Sorbitol Dehydrogenase (SORD) Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Sorbitol dehydrogenase deficiency (SORD Deficiency) is a progressive hereditary neuropathy that significantly impacts peripheral nerves and motor neurons, leading to considerable disability, sensory loss, and reduced mobility. Consequently, intracellular sorbitol accumulates, and this molecular alteration has been identified as the underlying cause of the disease in a specific subgroup of patients previously diagnosed with Charcot-Marie-Tooth disease (CMT2) or distal hereditary motor neuropathy (dHMN). A subtype of Charcot-Marie-Tooth disease (CMT) is caused by a mutated SORD gene, which encodes for sorbitol dehydrogenase. The mutated gene results in elevated levels of sorbitol, leading to axonal damage in the peripheral nerves. Individuals with SORD Deficiency experience a progressive form of neuropathy, typically commencing in late adolescence. This condition can substantially impede the individual’s quality of life, presenting symptoms such as limb weakness, foot deformities, tremors, sensory impairment, and difficulties with walking. Onset of SORD Deficiency symptoms typically occurs around the age of 17, although it can arise anytime between 9 and 25 years of age. Clinical diagnosis of SORD Deficiency relies on the presence of a slowly progressing neuropathy, often accompanied by foot deformities. In addition to clinical assessment of signs, symptoms, and neurophysiological evaluations, SORD Deficiency can also be confirmed through genetic testing and motor nerve conduction velocity (MNCV) testing. Currently, there are no approved pharmacological treatments for SORD Deficiency. Management of symptoms involves a multidisciplinary approach, including rehabilitative measures, physical and occupational therapy, and surgical interventions in cases of severe impairment.
• In the United States, it is estimated that there are around 3,300 individuals who carry mutations in the SORD gene that contribute to the development of the disorder.

Thelansis’s “Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sorbitol Dehydrogenase (SORD) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Sorbitol Dehydrogenase (SORD) Deficiency across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Sorbitol Dehydrogenase (SORD) Deficiency Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Sorbitol Dehydrogenase (SORD) Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033